[
  {
    "name": "ABACAVIR",
    "risk": "High",
    "severity": "Severe",
    "confidence": 0.97,
    "gene": "HLA-B",
    "diplotype": "*57:01",
    "phenotype": "Hypersensitivity Risk",
    "phenotypeLabel": "Immune Reaction",
    "cpic": "Level A",
    "dosage": "Avoid use",
    "alternative": "Tenofovir",
    "mechanism": "Immune-mediated reaction",
    "whyRisk": "HLA-B*57:01 associated with severe hypersensitivity",
    "variants": ["rs2395029"],
    "geneImpact": 98,
    "category": "Infectious Disease"
  },
  {
    "name": "AMITRIPTYLINE",
    "risk": "Moderate",
    "severity": "Moderate",
    "confidence": 0.90,
    "gene": "CYP2D6",
    "diplotype": "*4/*5",
    "phenotype": "Poor Metabolizer",
    "phenotypeLabel": "Reduced Clearance",
    "cpic": "Level A",
    "dosage": "Reduce dose",
    "alternative": "Sertraline",
    "mechanism": "Reduced metabolism",
    "whyRisk": "Elevated plasma concentration increases side effects",
    "variants": ["rs3892097"],
    "geneImpact": 85,
    "category": "Psychiatry"
  },
  {
    "name": "ATAZANAVIR",
    "risk": "Moderate",
    "severity": "Moderate",
    "confidence": 0.88,
    "gene": "UGT1A1",
    "diplotype": "*28/*28",
    "phenotype": "Poor Metabolizer",
    "phenotypeLabel": "Reduced Glucuronidation",
    "cpic": "Level A",
    "dosage": "Use with caution; monitor bilirubin",
    "alternative": "Darunavir",
    "mechanism": "Reduced UGT1A1-mediated glucuronidation increases drug and bilirubin levels",
    "whyRisk": "UGT1A1*28 homozygosity associated with hyperbilirubinemia and jaundice",
    "variants": ["rs8175347"],
    "geneImpact": 83,
    "category": "Infectious Disease"
  },
  {
    "name": "ATOMOXETINE",
    "risk": "Moderate",
    "severity": "Moderate",
    "confidence": 0.88,
    "gene": "CYP2D6",
    "diplotype": "*10/*4",
    "phenotype": "Intermediate Metabolizer",
    "phenotypeLabel": "Slower Metabolism",
    "cpic": "Level A",
    "dosage": "Adjust dose",
    "alternative": "Methylphenidate",
    "mechanism": "Reduced metabolism",
    "whyRisk": "Higher systemic exposure",
    "variants": ["rs1065852"],
    "geneImpact": 82,
    "category": "Psychiatry"
  },
  {
    "name": "AZATHIOPRINE",
    "risk": "High",
    "severity": "Severe",
    "confidence": 0.95,
    "gene": "TPMT",
    "diplotype": "*3A/*3C",
    "phenotype": "Low Activity",
    "phenotypeLabel": "Poor Metabolizer",
    "cpic": "Level A",
    "dosage": "Reduce drastically or avoid",
    "alternative": "Mycophenolate",
    "mechanism": "Impaired thiopurine metabolism",
    "whyRisk": "Severe myelosuppression risk",
    "variants": ["rs1142345"],
    "geneImpact": 93,
    "category": "Immunology"
  },
  {
    "name": "CAPECITABINE",
    "risk": "High",
    "severity": "Severe",
    "confidence": 0.96,
    "gene": "DPYD",
    "diplotype": "*2A",
    "phenotype": "Deficient Metabolizer",
    "phenotypeLabel": "Low DPD Activity",
    "cpic": "Level A",
    "dosage": "Avoid or reduce significantly",
    "alternative": "Non-fluoropyrimidine therapy",
    "mechanism": "Reduced drug breakdown",
    "whyRisk": "Severe toxicity risk",
    "variants": ["rs3918290"],
    "geneImpact": 97,
    "category": "Oncology"
  },
  {
    "name": "CARBAMAZEPINE",
    "risk": "High",
    "severity": "Severe",
    "confidence": 0.94,
    "gene": "HLA-B",
    "diplotype": "*15:02",
    "phenotype": "High Risk",
    "phenotypeLabel": "Severe Cutaneous Reaction",
    "cpic": "Level A",
    "dosage": "Avoid use",
    "alternative": "Levetiracetam",
    "mechanism": "Immune reaction",
    "whyRisk": "Risk of Stevens-Johnson Syndrome",
    "variants": ["rs3909184"],
    "geneImpact": 95,
    "category": "Neurology"
  },
  {
    "name": "CELECOXIB",
    "risk": "Moderate",
    "severity": "Moderate",
    "confidence": 0.87,
    "gene": "CYP2C9",
    "diplotype": "*2/*3",
    "phenotype": "Poor Metabolizer",
    "phenotypeLabel": "Reduced Clearance",
    "cpic": "Level B",
    "dosage": "Reduce dose; use lowest effective dose",
    "alternative": "Naproxen (with caution)",
    "mechanism": "Reduced CYP2C9-mediated metabolism increases celecoxib plasma levels",
    "whyRisk": "CYP2C9 poor metabolizers have significantly elevated celecoxib exposure and GI/cardiovascular risk",
    "variants": ["rs1057910", "rs1799853"],
    "geneImpact": 84,
    "category": "Pain Management"
  },
  {
    "name": "CHLOROQUINE",
    "risk": "High",
    "severity": "Severe",
    "confidence": 0.91,
    "gene": "G6PD",
    "diplotype": "Deficient",
    "phenotype": "G6PD Deficiency",
    "phenotypeLabel": "Hemolytic Risk",
    "cpic": "Level A",
    "dosage": "Avoid use",
    "alternative": "Artemisinin-based therapy",
    "mechanism": "Oxidative stress in G6PD-deficient red blood cells triggers hemolysis",
    "whyRisk": "G6PD deficiency associated with drug-induced hemolytic anemia",
    "variants": ["rs1050828", "rs1050829"],
    "geneImpact": 90,
    "category": "Infectious Disease"
  },
  {
    "name": "CITALOPRAM",
    "risk": "Moderate",
    "severity": "Moderate",
    "confidence": 0.89,
    "gene": "CYP2C19",
    "diplotype": "*2/*2",
    "phenotype": "Poor Metabolizer",
    "phenotypeLabel": "Reduced Clearance",
    "cpic": "Level A",
    "dosage": "Reduce dose",
    "alternative": "Sertraline",
    "mechanism": "Reduced metabolism",
    "whyRisk": "QT prolongation risk",
    "variants": ["rs4244285"],
    "geneImpact": 84,
    "category": "Psychiatry"
  },
  {
    "name": "CLOMIPRAMINE",
    "risk": "Moderate",
    "severity": "Moderate",
    "confidence": 0.88,
    "gene": "CYP2D6",
    "diplotype": "*4/*4",
    "phenotype": "Poor Metabolizer",
    "phenotypeLabel": "Reduced Clearance",
    "cpic": "Level A",
    "dosage": "Reduce dose; monitor for toxicity",
    "alternative": "Sertraline",
    "mechanism": "Reduced CYP2D6-mediated metabolism increases clomipramine and desmethylclomipramine levels",
    "whyRisk": "Elevated tricyclic levels increase risk of cardiotoxicity and anticholinergic side effects",
    "variants": ["rs3892097"],
    "geneImpact": 84,
    "category": "Psychiatry"
  },
  {
    "name": "CLOPIDOGREL",
    "risk": "Moderate",
    "severity": "Moderate",
    "confidence": 0.88,
    "gene": "CYP2C19",
    "diplotype": "*2/*2",
    "phenotype": "Poor Metabolizer",
    "phenotypeLabel": "Reduced Activation",
    "cpic": "Level A",
    "dosage": "Increase dose or alternative",
    "alternative": "Prasugrel",
    "mechanism": "Reduced activation",
    "whyRisk": "Reduced antiplatelet effect",
    "variants": ["rs4244285"],
    "geneImpact": 85,
    "category": "Cardiology"
  },
  {
    "name": "CODEINE",
    "risk": "High",
    "severity": "Severe",
    "confidence": 0.95,
    "gene": "CYP2D6",
    "diplotype": "*1/*1xN",
    "phenotype": "Ultra-Rapid Metabolizer",
    "phenotypeLabel": "Excess Morphine Production",
    "cpic": "Level A",
    "dosage": "Avoid use",
    "alternative": "Morphine",
    "mechanism": "Increased conversion",
    "whyRisk": "Respiratory depression risk",
    "variants": ["rs1065852"],
    "geneImpact": 94,
    "category": "Pain Management"
  },
  {
    "name": "CYCLOSPORINE",
    "risk": "Moderate",
    "severity": "Moderate",
    "confidence": 0.89,
    "gene": "CYP3A5",
    "diplotype": "*1/*3",
    "phenotype": "Intermediate Expresser",
    "phenotypeLabel": "Variable Metabolism",
    "cpic": "Level B",
    "dosage": "Monitor drug levels; adjust dose accordingly",
    "alternative": "Tacrolimus",
    "mechanism": "Variable CYP3A5 expression affects cyclosporine clearance",
    "whyRisk": "Unpredictable drug exposure increases nephrotoxicity or rejection risk",
    "variants": ["rs776746"],
    "geneImpact": 80,
    "category": "Transplant"
  },
  {
    "name": "DAPSONE",
    "risk": "High",
    "severity": "Severe",
    "confidence": 0.92,
    "gene": "G6PD",
    "diplotype": "Deficient",
    "phenotype": "G6PD Deficiency",
    "phenotypeLabel": "Hemolytic Risk",
    "cpic": "Level A",
    "dosage": "Avoid use",
    "alternative": "Trimethoprim-sulfamethoxazole",
    "mechanism": "Oxidative hemolysis in G6PD-deficient erythrocytes",
    "whyRisk": "G6PD deficiency leads to severe hemolytic anemia with dapsone use",
    "variants": ["rs1050828", "rs1050829"],
    "geneImpact": 91,
    "category": "Infectious Disease"
  },
  {
    "name": "DESIPRAMINE",
    "risk": "Moderate",
    "severity": "Moderate",
    "confidence": 0.88,
    "gene": "CYP2D6",
    "diplotype": "*4/*4",
    "phenotype": "Poor Metabolizer",
    "phenotypeLabel": "Reduced Clearance",
    "cpic": "Level A",
    "dosage": "Reduce dose; monitor plasma levels",
    "alternative": "Sertraline",
    "mechanism": "Reduced CYP2D6 metabolism leads to elevated plasma desipramine",
    "whyRisk": "High plasma levels increase risk of arrhythmia and anticholinergic toxicity",
    "variants": ["rs3892097"],
    "geneImpact": 83,
    "category": "Psychiatry"
  },
  {
    "name": "DICLOFENAC",
    "risk": "Moderate",
    "severity": "Moderate",
    "confidence": 0.86,
    "gene": "CYP2C9",
    "diplotype": "*1/*3",
    "phenotype": "Intermediate Metabolizer",
    "phenotypeLabel": "Reduced Clearance",
    "cpic": "Level B",
    "dosage": "Consider dose reduction",
    "alternative": "Celecoxib (with CYP2C9 consideration)",
    "mechanism": "Reduced CYP2C9-mediated metabolism increases diclofenac exposure",
    "whyRisk": "Elevated exposure increases risk of GI bleeding and hepatotoxicity",
    "variants": ["rs1057910", "rs1799853"],
    "geneImpact": 80,
    "category": "Pain Management"
  },
  {
    "name": "DOXEPIN",
    "risk": "Moderate",
    "severity": "Moderate",
    "confidence": 0.87,
    "gene": "CYP2D6",
    "diplotype": "*4/*5",
    "phenotype": "Poor Metabolizer",
    "phenotypeLabel": "Reduced Clearance",
    "cpic": "Level A",
    "dosage": "Reduce dose; monitor for adverse effects",
    "alternative": "Sertraline",
    "mechanism": "Impaired CYP2D6-mediated metabolism increases doxepin and nordoxepin concentrations",
    "whyRisk": "Elevated tricyclic levels raise risk of sedation, QT prolongation, and anticholinergic toxicity",
    "variants": ["rs3892097"],
    "geneImpact": 83,
    "category": "Psychiatry"
  },
  {
    "name": "EFAVIRENZ",
    "risk": "Moderate",
    "severity": "Moderate",
    "confidence": 0.89,
    "gene": "CYP2B6",
    "diplotype": "*6/*6",
    "phenotype": "Poor Metabolizer",
    "phenotypeLabel": "Reduced Clearance",
    "cpic": "Level B",
    "dosage": "Reduce dose; monitor plasma levels",
    "alternative": "Dolutegravir",
    "mechanism": "Reduced CYP2B6 activity increases efavirenz plasma concentrations",
    "whyRisk": "Elevated efavirenz levels increase risk of CNS toxicity and hepatotoxicity",
    "variants": ["rs3745274"],
    "geneImpact": 85,
    "category": "Infectious Disease"
  },
  {
    "name": "ERLOTINIB",
    "risk": "Low",
    "severity": "Mild",
    "confidence": 0.84,
    "gene": "EGFR",
    "diplotype": "*1/*1",
    "phenotype": "Normal",
    "phenotypeLabel": "Normal Activity",
    "cpic": "Level B",
    "dosage": "Standard dosing",
    "alternative": "",
    "mechanism": "EGFR tyrosine kinase inhibition",
    "whyRisk": "No clinically actionable pharmacogenomic variants detected for erlotinib metabolism",
    "variants": [],
    "geneImpact": 72,
    "category": "Oncology"
  },
  {
    "name": "ESCITALOPRAM",
    "risk": "Moderate",
    "severity": "Moderate",
    "confidence": 0.88,
    "gene": "CYP2C19",
    "diplotype": "*2/*2",
    "phenotype": "Poor Metabolizer",
    "phenotypeLabel": "Reduced Clearance",
    "cpic": "Level A",
    "dosage": "Reduce dose; do not exceed 10 mg/day",
    "alternative": "Sertraline",
    "mechanism": "Reduced CYP2C19-mediated metabolism increases escitalopram plasma levels",
    "whyRisk": "Elevated levels increase risk of QT prolongation and serotonin syndrome",
    "variants": ["rs4244285"],
    "geneImpact": 84,
    "category": "Psychiatry"
  },
  {
    "name": "FLUOROURACIL",
    "risk": "High",
    "severity": "Severe",
    "confidence": 0.96,
    "gene": "DPYD",
    "diplotype": "*2A",
    "phenotype": "Poor Metabolizer",
    "phenotypeLabel": "Low DPD Activity",
    "cpic": "Level A",
    "dosage": "Avoid or major reduction",
    "alternative": "Alternative chemotherapy",
    "mechanism": "Reduced degradation",
    "whyRisk": "Life-threatening toxicity",
    "variants": ["rs3918290"],
    "geneImpact": 97,
    "category": "Oncology"
  },
  {
    "name": "FLUVASTATIN",
    "risk": "Moderate",
    "severity": "Moderate",
    "confidence": 0.86,
    "gene": "CYP2C9",
    "diplotype": "*2/*3",
    "phenotype": "Poor Metabolizer",
    "phenotypeLabel": "Reduced Clearance",
    "cpic": "Level B",
    "dosage": "Use lowest effective dose",
    "alternative": "Pravastatin",
    "mechanism": "Reduced CYP2C9-mediated metabolism increases fluvastatin exposure",
    "whyRisk": "Elevated statin exposure increases myopathy and rhabdomyolysis risk",
    "variants": ["rs1057910", "rs1799853"],
    "geneImpact": 81,
    "category": "Cardiology"
  },
  {
    "name": "FLUVOXAMINE",
    "risk": "Moderate",
    "severity": "Moderate",
    "confidence": 0.87,
    "gene": "CYP2D6",
    "diplotype": "*4/*4",
    "phenotype": "Poor Metabolizer",
    "phenotypeLabel": "Reduced Clearance",
    "cpic": "Level A",
    "dosage": "Reduce dose; monitor for adverse effects",
    "alternative": "Sertraline",
    "mechanism": "Reduced CYP2D6 metabolism and strong CYP1A2/CYP2C19 inhibition increases drug levels",
    "whyRisk": "Elevated plasma levels increase risk of serotonin syndrome and QT prolongation",
    "variants": ["rs3892097"],
    "geneImpact": 82,
    "category": "Psychiatry"
  },
  {
    "name": "GEFITINIB",
    "risk": "Low",
    "severity": "Mild",
    "confidence": 0.85,
    "gene": "EGFR",
    "diplotype": "*1/*1",
    "phenotype": "Normal",
    "phenotypeLabel": "Normal Activity",
    "cpic": "Level B",
    "dosage": "Standard dosing",
    "alternative": "",
    "mechanism": "EGFR pathway inhibition",
    "whyRisk": "No known PGx interaction",
    "variants": [],
    "geneImpact": 75,
    "category": "Oncology"
  },
  {
    "name": "GLIMEPIRIDE",
    "risk": "Moderate",
    "severity": "Moderate",
    "confidence": 0.86,
    "gene": "CYP2C9",
    "diplotype": "*2/*3",
    "phenotype": "Poor Metabolizer",
    "phenotypeLabel": "Reduced Clearance",
    "cpic": "Level B",
    "dosage": "Reduce dose; monitor blood glucose closely",
    "alternative": "Glipizide (with dose adjustment)",
    "mechanism": "Reduced CYP2C9-mediated metabolism increases glimepiride plasma levels",
    "whyRisk": "Elevated sulfonylurea exposure increases hypoglycemia risk",
    "variants": ["rs1057910", "rs1799853"],
    "geneImpact": 82,
    "category": "Endocrinology"
  },
  {
    "name": "IBUPROFEN",
    "risk": "Moderate",
    "severity": "Moderate",
    "confidence": 0.85,
    "gene": "CYP2C9",
    "diplotype": "*1/*3",
    "phenotype": "Intermediate Metabolizer",
    "phenotypeLabel": "Reduced Clearance",
    "cpic": "Level B",
    "dosage": "Use lowest effective dose; consider alternatives",
    "alternative": "Acetaminophen",
    "mechanism": "Reduced CYP2C9-mediated ibuprofen metabolism increases plasma exposure",
    "whyRisk": "Elevated NSAID levels increase risk of GI bleeding and renal impairment",
    "variants": ["rs1057910"],
    "geneImpact": 78,
    "category": "Pain Management"
  },
  {
    "name": "IMATINIB",
    "risk": "Low",
    "severity": "Mild",
    "confidence": 0.83,
    "gene": "CYP3A4",
    "diplotype": "*1/*1",
    "phenotype": "Normal Metabolizer",
    "phenotypeLabel": "Normal Clearance",
    "cpic": "Level B",
    "dosage": "Standard dosing",
    "alternative": "",
    "mechanism": "CYP3A4-mediated metabolism; no clinically actionable variants detected",
    "whyRisk": "No significant pharmacogenomic risk identified; drug-drug interactions may be more clinically relevant",
    "variants": [],
    "geneImpact": 70,
    "category": "Oncology"
  },
  {
    "name": "IMIPRAMINE",
    "risk": "Moderate",
    "severity": "Moderate",
    "confidence": 0.88,
    "gene": "CYP2D6",
    "diplotype": "*4/*4",
    "phenotype": "Poor Metabolizer",
    "phenotypeLabel": "Reduced Clearance",
    "cpic": "Level A",
    "dosage": "Reduce dose; monitor plasma levels",
    "alternative": "Sertraline",
    "mechanism": "Reduced CYP2D6 metabolism elevates imipramine and desipramine concentrations",
    "whyRisk": "Increased tricyclic levels raise risk of cardiotoxicity and anticholinergic effects",
    "variants": ["rs3892097"],
    "geneImpact": 84,
    "category": "Psychiatry"
  },
  {
    "name": "IRINOTECAN",
    "risk": "High",
    "severity": "Severe",
    "confidence": 0.94,
    "gene": "UGT1A1",
    "diplotype": "*28/*28",
    "phenotype": "Poor Metabolizer",
    "phenotypeLabel": "Reduced Glucuronidation",
    "cpic": "Level A",
    "dosage": "Reduce starting dose",
    "alternative": "Oxaliplatin-based regimen",
    "mechanism": "Reduced UGT1A1-mediated glucuronidation of SN-38 active metabolite",
    "whyRisk": "UGT1A1*28 homozygosity leads to severe neutropenia and diarrhea",
    "variants": ["rs8175347"],
    "geneImpact": 93,
    "category": "Oncology"
  },
  {
    "name": "LAPATINIB",
    "risk": "Low",
    "severity": "Mild",
    "confidence": 0.82,
    "gene": "CYP3A4",
    "diplotype": "*1/*1",
    "phenotype": "Normal Metabolizer",
    "phenotypeLabel": "Normal Clearance",
    "cpic": "Level B",
    "dosage": "Standard dosing",
    "alternative": "",
    "mechanism": "CYP3A4-mediated metabolism; no high-impact PGx variants identified",
    "whyRisk": "No clinically actionable pharmacogenomic variants; drug-drug interactions are primary concern",
    "variants": [],
    "geneImpact": 68,
    "category": "Oncology"
  },
  {
    "name": "LOVASTATIN",
    "risk": "Moderate",
    "severity": "Moderate",
    "confidence": 0.87,
    "gene": "SLCO1B1",
    "diplotype": "*5/*5",
    "phenotype": "Low Function",
    "phenotypeLabel": "Reduced Transport",
    "cpic": "Level A",
    "dosage": "Use lowest effective dose",
    "alternative": "Pravastatin",
    "mechanism": "Reduced SLCO1B1-mediated hepatic uptake increases systemic lovastatin exposure",
    "whyRisk": "Elevated plasma lovastatin levels increase myopathy and rhabdomyolysis risk",
    "variants": ["rs4149056"],
    "geneImpact": 82,
    "category": "Cardiology"
  },
  {
    "name": "MERCAPTOPURINE",
    "risk": "High",
    "severity": "Severe",
    "confidence": 0.95,
    "gene": "TPMT",
    "diplotype": "*3A/*3C",
    "phenotype": "Poor Metabolizer",
    "phenotypeLabel": "Low TPMT Activity",
    "cpic": "Level A",
    "dosage": "Drastically reduce dose or avoid",
    "alternative": "Mycophenolate",
    "mechanism": "Reduced TPMT activity causes accumulation of cytotoxic thioguanine nucleotides",
    "whyRisk": "Severe myelosuppression and life-threatening bone marrow toxicity",
    "variants": ["rs1142345"],
    "geneImpact": 94,
    "category": "Oncology"
  },
  {
    "name": "METFORMIN",
    "risk": "Low",
    "severity": "Mild",
    "confidence": 0.88,
    "gene": "SLC22A1",
    "diplotype": "*1/*1",
    "phenotype": "Normal Transporter Function",
    "phenotypeLabel": "Normal Response",
    "cpic": "Level B",
    "dosage": "Standard dosing",
    "alternative": "",
    "mechanism": "Reduced hepatic glucose production via AMPK activation",
    "whyRisk": "No clinically actionable pharmacogenomic variants detected affecting metformin transport or clearance.",
    "variants": ["rs622342"],
    "geneImpact": 72,
    "category": "Endocrinology"
  },
  {
    "name": "METOPROLOL",
    "risk": "Moderate",
    "severity": "Moderate",
    "confidence": 0.89,
    "gene": "CYP2D6",
    "diplotype": "*4/*4",
    "phenotype": "Poor Metabolizer",
    "phenotypeLabel": "Reduced Clearance",
    "cpic": "Level A",
    "dosage": "Reduce dose; titrate carefully",
    "alternative": "Atenolol",
    "mechanism": "Reduced CYP2D6-mediated metabolism significantly increases metoprolol plasma levels",
    "whyRisk": "Elevated metoprolol levels increase risk of bradycardia and hypotension",
    "variants": ["rs3892097"],
    "geneImpact": 86,
    "category": "Cardiology"
  },
  {
    "name": "MYCOPHENOLATE",
    "risk": "Low",
    "severity": "Mild",
    "confidence": 0.83,
    "gene": "UGT1A9",
    "diplotype": "*1/*1",
    "phenotype": "Normal Metabolizer",
    "phenotypeLabel": "Normal Glucuronidation",
    "cpic": "Level B",
    "dosage": "Standard dosing",
    "alternative": "",
    "mechanism": "UGT1A9-mediated glucuronidation; no high-impact variants detected",
    "whyRisk": "No clinically actionable pharmacogenomic variants identified for mycophenolate",
    "variants": [],
    "geneImpact": 68,
    "category": "Immunology"
  },
  {
    "name": "NORTRIPTYLINE",
    "risk": "Moderate",
    "severity": "Moderate",
    "confidence": 0.90,
    "gene": "CYP2D6",
    "diplotype": "*4/*5",
    "phenotype": "Poor Metabolizer",
    "phenotypeLabel": "Reduced Clearance",
    "cpic": "Level A",
    "dosage": "Reduce dose; monitor plasma levels",
    "alternative": "Sertraline",
    "mechanism": "Reduced CYP2D6 metabolism elevates nortriptyline plasma concentrations",
    "whyRisk": "Increased tricyclic levels raise risk of cardiotoxicity and anticholinergic effects",
    "variants": ["rs3892097"],
    "geneImpact": 86,
    "category": "Psychiatry"
  },
  {
    "name": "OLANZAPINE",
    "risk": "Moderate",
    "severity": "Moderate",
    "confidence": 0.86,
    "gene": "CYP1A2",
    "diplotype": "*1F/*1F",
    "phenotype": "Ultra-Rapid Metabolizer",
    "phenotypeLabel": "Increased Clearance",
    "cpic": "Level B",
    "dosage": "May require higher dose; monitor therapeutic response",
    "alternative": "Risperidone",
    "mechanism": "Increased CYP1A2-mediated metabolism reduces olanzapine plasma levels",
    "whyRisk": "Subtherapeutic olanzapine levels may lead to treatment failure",
    "variants": ["rs762551"],
    "geneImpact": 78,
    "category": "Psychiatry"
  },
  {
    "name": "ONDANSETRON",
    "risk": "Moderate",
    "severity": "Moderate",
    "confidence": 0.88,
    "gene": "CYP2D6",
    "diplotype": "*4/*4",
    "phenotype": "Poor Metabolizer",
    "phenotypeLabel": "Reduced Clearance",
    "cpic": "Level A",
    "dosage": "Reduce dose; avoid doses >8mg",
    "alternative": "Granisetron",
    "mechanism": "Reduced CYP2D6 metabolism increases ondansetron plasma concentration",
    "whyRisk": "Elevated ondansetron levels increase QT prolongation risk",
    "variants": ["rs3892097"],
    "geneImpact": 83,
    "category": "Oncology"
  },
  {
    "name": "OXCARBAZEPINE",
    "risk": "High",
    "severity": "Severe",
    "confidence": 0.92,
    "gene": "HLA-B",
    "diplotype": "*15:02",
    "phenotype": "High Risk",
    "phenotypeLabel": "Severe Cutaneous Reaction",
    "cpic": "Level A",
    "dosage": "Avoid use",
    "alternative": "Levetiracetam",
    "mechanism": "Immune-mediated reaction via HLA-B*15:02 presentation",
    "whyRisk": "HLA-B*15:02 strongly associated with Stevens-Johnson Syndrome / TEN with oxcarbazepine",
    "variants": ["rs3909184"],
    "geneImpact": 92,
    "category": "Neurology"
  },
  {
    "name": "OXYCODONE",
    "risk": "Moderate",
    "severity": "Moderate",
    "confidence": 0.87,
    "gene": "CYP2D6",
    "diplotype": "*4/*4",
    "phenotype": "Poor Metabolizer",
    "phenotypeLabel": "Reduced Activation",
    "cpic": "Level B",
    "dosage": "Use standard dose; reduced conversion to active metabolite",
    "alternative": "Morphine",
    "mechanism": "Reduced CYP2D6-mediated conversion to oxymorphone reduces analgesic efficacy",
    "whyRisk": "Poor metabolizers may experience reduced pain relief; ultra-rapid metabolizers risk toxicity",
    "variants": ["rs3892097"],
    "geneImpact": 79,
    "category": "Pain Management"
  },
  {
    "name": "PAROXETINE",
    "risk": "Moderate",
    "severity": "Moderate",
    "confidence": 0.89,
    "gene": "CYP2D6",
    "diplotype": "*4/*4",
    "phenotype": "Poor Metabolizer",
    "phenotypeLabel": "Reduced Clearance",
    "cpic": "Level A",
    "dosage": "Reduce dose; monitor for adverse effects",
    "alternative": "Sertraline",
    "mechanism": "Reduced CYP2D6-mediated metabolism increases paroxetine plasma levels",
    "whyRisk": "Elevated levels increase risk of serotonin syndrome and QT prolongation",
    "variants": ["rs3892097"],
    "geneImpact": 84,
    "category": "Psychiatry"
  },
  {
    "name": "PHENYTOIN",
    "risk": "High",
    "severity": "Severe",
    "confidence": 0.93,
    "gene": "CYP2C9",
    "diplotype": "*2/*3",
    "phenotype": "Poor Metabolizer",
    "phenotypeLabel": "Reduced Clearance",
    "cpic": "Level A",
    "dosage": "Reduce dose",
    "alternative": "Levetiracetam",
    "mechanism": "Reduced metabolism",
    "whyRisk": "Toxic plasma concentration",
    "variants": ["rs1057910"],
    "geneImpact": 90,
    "category": "Neurology"
  },
  {
    "name": "PIROXICAM",
    "risk": "Moderate",
    "severity": "Moderate",
    "confidence": 0.87,
    "gene": "CYP2C9",
    "diplotype": "*1/*3",
    "phenotype": "Intermediate Metabolizer",
    "phenotypeLabel": "Reduced Clearance",
    "cpic": "Level B",
    "dosage": "Consider dose reduction",
    "alternative": "Celecoxib",
    "mechanism": "Reduced CYP2C9-mediated metabolism increases plasma concentration",
    "whyRisk": "CYP2C9 reduced function alleles may increase NSAID exposure and gastrointestinal toxicity risk.",
    "variants": ["rs1057910", "rs1799853"],
    "geneImpact": 85,
    "category": "Pain Management"
  },
  {
    "name": "PRAVASTATIN",
    "risk": "Low",
    "severity": "Mild",
    "confidence": 0.84,
    "gene": "SLCO1B1",
    "diplotype": "*1/*1",
    "phenotype": "Normal Function",
    "phenotypeLabel": "Normal Transport",
    "cpic": "Level B",
    "dosage": "Standard dosing",
    "alternative": "",
    "mechanism": "SLCO1B1-mediated hepatic uptake; normal transporter function",
    "whyRisk": "No clinically significant pharmacogenomic risk; preferred statin for patients with SLCO1B1 variants",
    "variants": ["rs4149056"],
    "geneImpact": 65,
    "category": "Cardiology"
  },
  {
    "name": "PRIMAQUINE",
    "risk": "High",
    "severity": "Severe",
    "confidence": 0.93,
    "gene": "G6PD",
    "diplotype": "Deficient",
    "phenotype": "G6PD Deficiency",
    "phenotypeLabel": "Hemolytic Risk",
    "cpic": "Level A",
    "dosage": "Avoid use",
    "alternative": "Chloroquine (if G6PD normal)",
    "mechanism": "Oxidative stress in G6PD-deficient erythrocytes triggers hemolysis",
    "whyRisk": "G6PD deficiency leads to severe drug-induced hemolytic anemia",
    "variants": ["rs1050828", "rs1050829"],
    "geneImpact": 92,
    "category": "Infectious Disease"
  },
  {
    "name": "RASBURICASE",
    "risk": "High",
    "severity": "Severe",
    "confidence": 0.94,
    "gene": "G6PD",
    "diplotype": "Deficient",
    "phenotype": "G6PD Deficiency",
    "phenotypeLabel": "Hemolytic Risk",
    "cpic": "Level A",
    "dosage": "Contraindicated",
    "alternative": "Allopurinol",
    "mechanism": "Rasburicase generates hydrogen peroxide; G6PD deficiency prevents neutralization, causing hemolysis",
    "whyRisk": "G6PD deficiency is an absolute contraindication for rasburicase",
    "variants": ["rs1050828", "rs1050829"],
    "geneImpact": 95,
    "category": "Oncology"
  },
  {
    "name": "RISPERIDONE",
    "risk": "Moderate",
    "severity": "Moderate",
    "confidence": 0.87,
    "gene": "CYP2D6",
    "diplotype": "*4/*4",
    "phenotype": "Poor Metabolizer",
    "phenotypeLabel": "Reduced Clearance",
    "cpic": "Level B",
    "dosage": "Reduce dose; monitor for EPS and metabolic effects",
    "alternative": "Quetiapine",
    "mechanism": "Reduced CYP2D6-mediated metabolism increases risperidone and 9-hydroxyrisperidone levels",
    "whyRisk": "Elevated antipsychotic levels increase risk of extrapyramidal symptoms and metabolic side effects",
    "variants": ["rs3892097"],
    "geneImpact": 81,
    "category": "Psychiatry"
  },
  {
    "name": "SERTRALINE",
    "risk": "Low",
    "severity": "Mild",
    "confidence": 0.85,
    "gene": "CYP2C19",
    "diplotype": "*1/*1",
    "phenotype": "Normal Metabolizer",
    "phenotypeLabel": "Normal Clearance",
    "cpic": "Level A",
    "dosage": "Standard dosing",
    "alternative": "",
    "mechanism": "CYP2C19-mediated metabolism; normal enzyme activity",
    "whyRisk": "No clinically significant pharmacogenomic risk identified with normal CYP2C19 function",
    "variants": ["rs4244285"],
    "geneImpact": 70,
    "category": "Psychiatry"
  },
  {
    "name": "SIMVASTATIN",
    "risk": "Moderate",
    "severity": "Moderate",
    "confidence": 0.87,
    "gene": "SLCO1B1",
    "diplotype": "*5/*5",
    "phenotype": "Low Function",
    "phenotypeLabel": "Reduced Transport",
    "cpic": "Level A",
    "dosage": "Lower dose",
    "alternative": "Pravastatin",
    "mechanism": "Reduced hepatic uptake",
    "whyRisk": "Myopathy risk",
    "variants": ["rs4149056"],
    "geneImpact": 80,
    "category": "Cardiology"
  },
  {
    "name": "SIROLIMUS",
    "risk": "Moderate",
    "severity": "Moderate",
    "confidence": 0.88,
    "gene": "CYP3A5",
    "diplotype": "*1/*3",
    "phenotype": "Intermediate Expresser",
    "phenotypeLabel": "Variable Metabolism",
    "cpic": "Level B",
    "dosage": "Monitor trough levels; adjust dose accordingly",
    "alternative": "Everolimus",
    "mechanism": "CYP3A5 expression variability affects sirolimus clearance",
    "whyRisk": "Variable drug exposure increases risk of toxicity or subtherapeutic immunosuppression",
    "variants": ["rs776746"],
    "geneImpact": 79,
    "category": "Transplant"
  },
  {
    "name": "TACROLIMUS",
    "risk": "Moderate",
    "severity": "Moderate",
    "confidence": 0.91,
    "gene": "CYP3A5",
    "diplotype": "*3/*3",
    "phenotype": "Non-Expresser",
    "phenotypeLabel": "Reduced Clearance",
    "cpic": "Level A",
    "dosage": "Lower initial dose",
    "alternative": "Sirolimus",
    "mechanism": "Reduced metabolism",
    "whyRisk": "Nephrotoxicity risk",
    "variants": ["rs776746"],
    "geneImpact": 88,
    "category": "Transplant"
  },
  {
    "name": "TAMOXIFEN",
    "risk": "High",
    "severity": "Severe",
    "confidence": 0.93,
    "gene": "CYP2D6",
    "diplotype": "*4/*4",
    "phenotype": "Poor Metabolizer",
    "phenotypeLabel": "Reduced Activation",
    "cpic": "Level A",
    "dosage": "Consider alternative",
    "alternative": "Aromatase inhibitor (e.g., Letrozole)",
    "mechanism": "Reduced CYP2D6-mediated conversion to active endoxifen metabolite",
    "whyRisk": "Significantly reduced endoxifen levels lead to decreased efficacy in breast cancer treatment",
    "variants": ["rs3892097"],
    "geneImpact": 92,
    "category": "Oncology"
  },
  {
    "name": "TEGAFUR",
    "risk": "High",
    "severity": "Severe",
    "confidence": 0.95,
    "gene": "DPYD",
    "diplotype": "*2A",
    "phenotype": "Deficient Metabolizer",
    "phenotypeLabel": "Low DPD Activity",
    "cpic": "Level A",
    "dosage": "Avoid or significantly reduce dose",
    "alternative": "Non-fluoropyrimidine therapy",
    "mechanism": "Reduced DPYD-mediated catabolism of fluorouracil (tegafur prodrug) leads to toxic accumulation",
    "whyRisk": "DPYD deficiency causes severe, potentially fatal fluoropyrimidine toxicity",
    "variants": ["rs3918290"],
    "geneImpact": 96,
    "category": "Oncology"
  },
  {
    "name": "THIOGUANINE",
    "risk": "High",
    "severity": "Severe",
    "confidence": 0.94,
    "gene": "TPMT",
    "diplotype": "*3A/*3C",
    "phenotype": "Poor Metabolizer",
    "phenotypeLabel": "Low TPMT Activity",
    "cpic": "Level A",
    "dosage": "Drastically reduce dose or avoid",
    "alternative": "Mycophenolate",
    "mechanism": "Reduced TPMT activity causes accumulation of cytotoxic thioguanine nucleotides",
    "whyRisk": "Severe myelosuppression and life-threatening bone marrow toxicity",
    "variants": ["rs1142345"],
    "geneImpact": 93,
    "category": "Oncology"
  },
  {
    "name": "TRAMADOL",
    "risk": "High",
    "severity": "Severe",
    "confidence": 0.92,
    "gene": "CYP2D6",
    "diplotype": "*1/*1xN",
    "phenotype": "Ultra-Rapid Metabolizer",
    "phenotypeLabel": "Excess Active Metabolite",
    "cpic": "Level A",
    "dosage": "Avoid use",
    "alternative": "Morphine",
    "mechanism": "Increased CYP2D6-mediated conversion to O-desmethyltramadol (M1 active metabolite)",
    "whyRisk": "Ultra-rapid metabolizers risk respiratory depression and seizures from excess M1 accumulation",
    "variants": ["rs1065852"],
    "geneImpact": 91,
    "category": "Pain Management"
  },
  {
    "name": "TRIMIPRAMINE",
    "risk": "Moderate",
    "severity": "Moderate",
    "confidence": 0.86,
    "gene": "CYP2D6",
    "diplotype": "*4/*5",
    "phenotype": "Poor Metabolizer",
    "phenotypeLabel": "Reduced Clearance",
    "cpic": "Level A",
    "dosage": "Reduce dose; monitor for adverse effects",
    "alternative": "Sertraline",
    "mechanism": "Reduced CYP2D6-mediated metabolism increases trimipramine plasma levels",
    "whyRisk": "Elevated tricyclic levels increase risk of cardiotoxicity and sedation",
    "variants": ["rs3892097"],
    "geneImpact": 82,
    "category": "Psychiatry"
  },
  {
    "name": "VENLAFAXINE",
    "risk": "Moderate",
    "severity": "Moderate",
    "confidence": 0.88,
    "gene": "CYP2D6",
    "diplotype": "*4/*4",
    "phenotype": "Poor Metabolizer",
    "phenotypeLabel": "Reduced Clearance",
    "cpic": "Level A",
    "dosage": "Reduce dose; monitor for serotonergic effects",
    "alternative": "Duloxetine",
    "mechanism": "Reduced CYP2D6-mediated metabolism of venlafaxine to O-desmethylvenlafaxine",
    "whyRisk": "Altered venlafaxine-to-ODV ratio increases risk of serotonin syndrome and cardiovascular effects",
    "variants": ["rs3892097"],
    "geneImpact": 83,
    "category": "Psychiatry"
  },
  {
    "name": "VORICONAZOLE",
    "risk": "High",
    "severity": "Severe",
    "confidence": 0.93,
    "gene": "CYP2C19",
    "diplotype": "*2/*2",
    "phenotype": "Poor Metabolizer",
    "phenotypeLabel": "Reduced Clearance",
    "cpic": "Level A",
    "dosage": "Reduce dose; monitor plasma levels",
    "alternative": "Isavuconazole",
    "mechanism": "Reduced CYP2C19-mediated metabolism causes significant voriconazole accumulation",
    "whyRisk": "Highly elevated plasma levels increase risk of visual disturbances, neurotoxicity, and hepatotoxicity",
    "variants": ["rs4244285"],
    "geneImpact": 91,
    "category": "Infectious Disease"
  },
  {
    "name": "WARFARIN",
    "risk": "High",
    "severity": "Severe",
    "confidence": 0.92,
    "gene": "CYP2C9",
    "diplotype": "*2/*3",
    "phenotype": "Poor Metabolizer",
    "phenotypeLabel": "Low Enzyme Activity",
    "cpic": "Level A",
    "dosage": "Reduce dose significantly",
    "alternative": "Apixaban",
    "mechanism": "Reduced metabolism",
    "whyRisk": "Increased bleeding risk",
    "variants": ["rs1057910"],
    "geneImpact": 90,
    "category": "Cardiology"
  }
]